Tumor Cell Expression of Vascular Endothelial Growth Factor Receptor 2 Is an Adverse Prognostic Factor in Patients with Squamous Cell Carcinoma of the Lung

A robust immunohistochemical (IHC) assay for VEGFR2 was developed to investigate its utility for patient tailoring in clinical trials. The sensitivity, specificity, and selectivity of the IHC assay were established by siRNA knockdown, immunoblotting, mass spectrometry, and pre-absorption experiments...

Descripción completa

Detalles Bibliográficos
Autores principales: Holzer, Timothy R., Fulford, Angie D., Nedderman, Drew M., Umberger, Tara S., Hozak, Rebecca R., Joshi, Adarsh, Melemed, Symantha A., Benjamin, Laura E., Plowman, Gregory D., Schade, Andrew E., Ackermann, Bradley L., Konrad, Robert J., Nasir, Aejaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828187/
https://www.ncbi.nlm.nih.gov/pubmed/24244672
http://dx.doi.org/10.1371/journal.pone.0080292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828187/
https://www.ncbi.nlm.nih.gov/pubmed/24244672
http://dx.doi.org/10.1371/journal.pone.0080292

Ejemplares similares